Recent News

• 11.09.2026 - New Data at 2026 American Heart Association Scientific Sessions Highlight Cardiovascular Effects of Sotagliflozin on Thrombus Formation and in Hypertrophic Cardiomyopathy
• 11.05.2026 - Lexicon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Clinical Updates
• 10.29.2026 - Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026
• 10.23.2026 - Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy
• 10.21.2026 - Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease
• 09.01.2026 - Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences
• 08.31.2026 - Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure
• 08.24.2026 - Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851
• 08.06.2026 - Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
• 07.27.2026 - Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)

Recent Filings

• 11.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 11.05.2026 - EX-99.1 EX-99.1
• 11.05.2026 - 8-K Current report
• 11.05.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.05.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.14.2026 - EFFECT Notice of Effectiveness
• 08.06.2026 - S-3 Registration statement under Securities Act of 1933
• 08.06.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 08.06.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.06.2026 - 8-K Current report